Treatment algorithm for multiple myeloma: Real-world insights across five European countriesA. RocciP. BulgerA. Martinez de PinillosP. NasutiC. AngerF. ManuguidAnnals of Oncology
The treatment of multiple myeloma (MM) continues to evolve rapidly with arrival of multiple new drugs, and emerging data from randomized trials to guide therapy. Along the disease course, the choice of specific therapy is affected by many variables including age, performance status, comorbidities, ...
Blood Cancer Journal www.nature.com/bcj CURRENT TREATMENT ALGORITHM OPEN Smoldering multiple myeloma current treatment algorithms S. Vincent Rajkumar 1 ✉, Shaji Kumar 1, Sagar Lonial 2 and Maria Victoria Mateos 3 © The Author(s) 2022 Smoldering multiple myeloma (SMM) is an asymptomatic ...
Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins. Leukemia & lymphoma 57, 537-556, doi: 10.3109/10428194.2015.1102245 (2016).Magarotto V, Salvini M, Bonello F, Bringhen S, Palumbo A. Strategy for the treatment of multiple myeloma utilizing ...
Myeloma is a cancer of plasma cells in the blood. It develops in the bone marrow, the soft, spongy tissue in the center of large bones where most blood cells are produced. Plasma cells are white blood cells that are part of the immune system. They produc
There are computer software programs that will need a new algorithm with a slightly different cocktail for folks with myeloma. Once that is done, we’re very optimistic about getting the test into use, because this type of flow cytometry is widely used at centers across the country and worl...
Multiple myeloma (MM) is a cancer of mature plasma cells, which are a type of white blood cell that produces immunoglobulins (antibodies).
Multiple myeloma (MM) is the second most prevalent hematologic malignancy characterized by a high synthesis rate of disulfide bond-rich proteins and chronic oxidative stress. However, the relationship between disulfidptosis and MM is still unclear. Methods: Using the non-negative ...
At the same time, novel antimyeloma therapies, newer risk stratification and staging tools are transforming the treatment algorithm. We examine the changing role of transplantation in myeloma in the context of novel drug therapy, biologic risk stratification and improving supportive care while arguing ...
mutation or loss and high disease burden. Various trials are also studying these agents as first line options in the newly diagnosed setting. These agents play an important role in the relapsed setting, and efforts are underway to optimize their sequencing in the myeloma treatment algorithm. ...